Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   uniQure   /   Wat is de waarde van uniQure?

uniQure« Terug naar discussie overzicht

Wat is de waarde van uniQure?

Volgen
7.824 Posts
Pagina: «« 1 ... 351 352 353 354 355 ... 392 »» | Laatste | Omlaag ↓
  1. flosz 22 oktober 2019 15:02
    P247
    A novel AAV-based miQURE gene therapy for SCA3 www.liebertpub.com/doi/10.1089/hum.20... twitter.com/floszcrxl/status/11866263...

    P336
    Prevalence and affinity/avidity assessment of pre-existing NABs against AAV2, 5 and 8 analyzed in the serum of 300 healthy donors www.liebertpub.com/doi/10.1089/hum.20... twitter.com/floszcrxl/status/11866266...

    P381
    Stem cell derived brain organoids, a promising model to study Adeno associated viruses for CNS gene therapy
    ABSTRACT WITHDRAWN www.liebertpub.com/doi/10.1089/hum.20...

    MRI-guided injections in the brain: a method for gene therapy delivery for NHP and humans www.liebertpub.com/doi/10.1089/hum.20... twitter.com/floszcrxl/status/11866255...

    twitter.com/floszcrxl/status/11865709...
  3. flosz 23 oktober 2019 18:21
    Prevalence and affinity/avidity assessment of pre-existing NABs against AAV2, 5 and 8 analyzed in the serum of 300 healthy donors $QURE #ESGCT19 uniqure.com/2019.10.24_ESGCT_Immunolo...

    Cell and Gene meeting on the Mesa, Jon Garen
    www.youtube.com/embed/2SuqxPmBsWI

    Panel: Cell and Gene Therapy for Neurological Product Indications $QURE $VYGR AskBio BlueRock

    www.youtube.com/watch?v=PaVgx6PQEBk
  5. Prof. Dollar 24 oktober 2019 21:47
    quote:

    Frontrunner schreef op 24 oktober 2019 21:27:

    Qure stijgt in afgelopen uur met vele procenten. Iemand een idee? Spark staat ook ruim in plus!
    Gerucht dat er door (nog bekend te maken) besluit van Federal Trade Commission zicht is op voortzetting overname van ONCE door Roche.
  6. Tex Mex 25 oktober 2019 11:41
    quote:

    Prof. Dollar schreef op 24 oktober 2019 21:47:

    [...]
    Gerucht dat er door (nog bekend te maken) besluit van Federal Trade Commission zicht is op voortzetting overname van ONCE door Roche.
    Het lijkt nu meer dan een gerucht te worden: FTC staff recommends approval of Roche deal for Spark.

    Reuters www.reuters.com/article/us-spark-m-a-...

    Zou dit de overnamespeculaties rondom uniQure weer gaan voeden?
    Hoe dan ook, met die paar honderd miljoen dollar extra op de bankrekening van QURE na de laatste aandelenuitgifte en met een almaar voortschrijdende ontwikkeling van de onderzoekspijplijn is het bedrijf dusdanig goed gepositioneerd dat het management geen overhaaste beslissingen hoeft te nemen.
    Met elke stap voorwaarts in de ontwikkelingspijplijn worden de risico’s in dit bedrijf kleiner en het bedrijf meer waard. De tijd zal niet in het nadeel werken van de lange termijn beleggers (wat veel van de bezoekers van dit uniQure forum volgens mij zijn).
  9. Prof. Dollar 28 oktober 2019 17:52
    uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress

    • Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec
    • Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of AMT-130 in Huntington’s Disease
    • Strong Balance Sheet with September 30, 2019 Cash and Cash Equivalents of $403 Million Expected to Fund Operations into Mid-2022
    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 28, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2019 and highlighted recent progress across its business.

    “We achieved a major company milestone for 2019 with the earlier than expected completion of full patient enrollment in the HOPE-B pivotal study of etranacogene dezaparvovec in hemophilia B, as well as the initiation of clinical sites and patient screening for the Phase I/II clinical study of AMT-130 in Huntington’s disease,” stated Matt Kapusta, chief executive officer of uniQure. “We also strengthened our balance sheet with new capital that we expect will fund operations into mid-2022 and allows us to deliver on key corporate goals across the business. We look forward to continuing our momentum through the remainder of the year and sharing our progress during what we believe will be a very productive 2020.”

    Volledig bericht: tools.eurolandir.com/tools/Pressrelea...
  10. T. Montana 29 oktober 2019 12:25
    Roche — surprise — delays $4.3B Spark buyout again as regulators hover (Endpoints News)

    Roche has yet again delayed their Spark buyout.

    The Swiss giant extended the window on the $4.3 billion gene therapy acquisition through November 25th. It is delay #8 for a deal first announced in February.

    Roche said the delay was to give UK and US regulators more time to review the acquisition. The Federal Trade Commission staff reviewing the deal reportedly recommended approval last week, months after a rare second information request some analysts thought could augur a divestiture demand. But a recommendation is not an official approval, and across the Atlantic, UK Competition and Markets Authority is not due to announce its Phase I decision until December 16.

    If the CMA decides the deal warrants a Phase II, it would initiate a more exhaustive probe.

    Roche CEO Severin Schwan has insisted the Spark acquisition will likely be completed by the end of the year, even as the company has prepared for a more protracted process. Schwan told investors in his third-quarter call last week he was confident the deal would be done before 2020, but the company filed back in July to extend the buyout’s final deadline 3 months to April 30.

    The regulatory process can be opaque and Roche has not commented on what lays behind the delays. Most of the speculation, though, has been that the holdup is over anticompetitive concerns around Roche’s hemophilia drug Hemlibra and a hemophilia gene therapy in development at Spark, SPK-8011.

    Conversely, investors have argued that regulators have been overly scrutinizing for a deal of this size and that the persistent delays have had a chilling effect on a gene therapy space that has answered once-big questions about its clinical feasibility but still has large blanks on the business end.
  13. flosz 30 oktober 2019 15:53
    Our CEO Matt Kapusta spoke with @Nasdaq's #BehindTheBell after Tuesday's Opening Bell Ceremony to talk about about what sets uniQure apart and how the company is working to revolutionize the treatment of genetic diseases through GT.
    www.youtube.com/watch?v=TXl5LOHl8uY
    twitter.com/uniqure_nv/status/1189555...
  14. pim f 30 oktober 2019 16:46
    quote:

    Prof. Dollar schreef op 27 september 2019 14:23:

    Het valt te bezien of het nieuwe data betreft. In juni presenteerde QURE '36 Weeks of Follow-Up Data'. En 36 weken maakt ook 9 maanden. tools.eurolandir.com/tools/Pressrelea...

    Nieuwe data verwacht ik pas tijdens de ASH Annual Meeting begin december.
    Op 10 mei van dit jaar werden de gegevens na 6 maanden AMT 061 gepresenteerd, dan verwacht je toch 12 maanden follow-up ergens de komende 2 weken? tinyurl.com/yymg2gl7
  16. Prof. Dollar 31 oktober 2019 12:51
    uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec tools.eurolandir.com/tools/Pressrelea...

    Zouden ze het bewust doen? In nagenoeg elke zin 'Etranacogene Dezaparvovec' opnemen. Zo van dan leren ze het wel te lezen en uit te spreken. EtraDeza, allitereert en bekt beter. Ik ben voor!
7.824 Posts
Pagina: «« 1 ... 351 352 353 354 355 ... 392 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
IMCD 152,900 +8,60 +5,96%
Aperam 27,360 +1,42 +5,47%
HEIJMANS KON 26,200 +1,10 +4,38%
UMG 23,710 +0,46 +1,98%
SBM Offshore 17,810 +0,28 +1,60%
RELX 44,640 +0,66 +1,50%
NSI 19,740 +0,26 +1,33%
Eurocommercial Properties 23,450 +0,30 +1,30%
CTP 14,700 +0,18 +1,24%
Ahold Delhaize 32,390 +0,34 +1,06%
WDP 21,200 +0,22 +1,05%
JUST EAT TAKEAWAY 11,295 +0,12 +1,03%
Vopak 43,080 +0,42 +0,98%
TKH 36,500 +0,32 +0,88%
Wolters Kluwer 161,850 +1,40 +0,87%
AMG Critical Materials N.V. 15,210 +0,13 +0,86%
Wereldhave 14,180 +0,12 +0,85%
Fagron 18,960 +0,16 +0,85%
KPN 3,618 +0,03 +0,81%
BESI 109,500 +0,70 +0,64%
JDE PEET'S 18,850 +0,07 +0,37%
Nedap N.V. 54,800 +0,20 +0,37%
Basic-Fit 22,820 +0,08 +0,35%
ACOMO 17,360 +0,04 +0,23%
BAM 4,160 +0,01 +0,19%
DSM FIRMENICH AG 104,800 +0,05 +0,05%
ING 14,990 +0,01 +0,04%
AZERION 1,296 0,00 0,00%
B&S Group SA 4,500 0,00 0,00%
Kendrion 11,000 0,00 0,00%
Vastned 24,500 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Alfen N.V. 11,700 -1,85 -13,65%
EBUSCO HOLDING 3,390 -0,46 -11,96%
ADYEN NV 1.272,600 -63,20 -4,73%
RANDSTAD NV 42,000 -1,52 -3,49%
INPOST 17,480 -0,47 -2,62%
Pharming 0,738 -0,02 -2,57%
PROSUS 38,440 -1,02 -2,57%
Fugro 16,760 -0,44 -2,56%
Philips Koninklijke 24,870 -0,63 -2,47%
Avantium 2,200 -0,05 -2,44%
Accsys 0,590 -0,01 -2,32%
THEON INTERNAT 8,980 -0,21 -2,29%
CM.COM 6,250 -0,13 -2,04%
FASTNED 21,800 -0,45 -2,02%
Air France-KLM 7,780 -0,16 -2,02%
Brunel 8,780 -0,18 -2,01%
ArcelorMittal 24,140 -0,49 -1,99%
Sif Holding 13,140 -0,24 -1,79%
Galapagos 25,120 -0,42 -1,64%
SIGNIFY NV 21,680 -0,36 -1,63%
Aegon 6,144 -0,09 -1,48%
NX FILTRATION 4,540 -0,07 -1,41%
ALLFUNDS GROUP 5,500 -0,07 -1,26%
PostNL 1,001 -0,01 -1,18%
SHELL PLC 31,250 -0,36 -1,15%
Akzo Nobel 58,820 -0,58 -0,98%
Corbion 22,360 -0,22 -0,97%
EXOR NV 94,650 -0,90 -0,94%
ASR Nederland 44,870 -0,32 -0,71%
ABN AMRO BANK N.V. 15,220 -0,10 -0,69%
TomTom 5,245 -0,04 -0,66%
ASMI 508,800 -2,80 -0,55%
ASML 621,500 -3,20 -0,51%
AEX 874,18 -4,36 -0,50%
Heineken 72,580 -0,36 -0,49%
Flow Traders 21,500 -0,10 -0,46%
RENEWI 7,360 -0,03 -0,41%
OCI 10,700 -0,04 -0,33%
UNILEVER PLC 54,560 -0,14 -0,26%
NN Group 45,130 -0,10 -0,22%
Sligro 11,160 -0,02 -0,18%
AMX 867,36 -1,40 -0,16%
ForFarmers 3,415 0,00 -0,15%
Van Lanschot Kempen NV 41,800 -0,05 -0,12%
ASCX 1.198,78 -1,05 -0,09%
Arcadis 65,100 -0,05 -0,08%
AALBERTS NV 35,120 -0,02 -0,06%
vlag naam koers verschil relatief verschil
AEX 874,18 -4,36 -0,50%
AEX GR 3.422,93 -17,05 -0,50%
Germany40^ 19.238,10 -124,42 -0,64%
FTSE 100 8.072,39 -68,35 -0,84%
EURO50 4.814,83 0,00 0,00%
US30^ 44.011,10 0,00 0,00%
Nasd100^ 21.123,70 0,00 0,00%
US500^ 6.000,22 0,00 0,00%
Japan225^ 39.109,80 0,00 0,00%
VD-NEW 15,36 -0,09 -0,58%
#/^ Index indications calculated real time, zie disclaimer